Key result
Enoxaparin thromboprophylaxis was associated with a 15% reduced odds of venous thromboembolism (OR 0.85) during index hospitalization compared with unfractionated heparin in medically ill patients.
Why the study?
Enoxaparin and UFH thromboprophylaxis reduce VTE in trials, but their comparative effectiveness and differences in hospital costs were unknown in US hospital practice.
Does enoxaparin reduce VTE events, mortality, and major bleeding compared to unfractionated heparin in medically ill hospitalized patients?
Cohort (n=376,858)
Yes
Does enoxaparin reduce VTE events, mortality, and major bleeding compared to unfractionated heparin in medically ill hospitalized patients?
Odds Ratio: 0.85 (95% CI 0.78–0.94)
Absolute Event Rate: 0.47% vs 0.76%
p-value: p=0.001
In a large real-world cohort of medically ill hospitalized patients, thromboprophylaxis with enoxaparin was associated with significantly lower rates of VTE, mortality, major bleeding, and hospital costs compared to unfractionated heparin.
No takes yet. Share an insight, caveat, or question.
Enoxaparin was associated with fewer VTE events, bleeding, and lower costs than UFH; leaves open optimal prophylaxis choice pending randomized trials.
Veeranki et al. (2020) conducted a cohort in Medically ill hospitalized patients at risk of venous thromboembolism (n=376,858). Enoxaparin vs. Unfractionated heparin (≤ 15,000 IU/day) was evaluated on Occurrence of venous thromboembolism (VTE) during index hospitalization (OR 0.85, 95% CI 0.78-0.94, p=0.001). Enoxaparin thromboprophylaxis was associated with a 15% reduced odds of venous thromboembolism (OR 0.85) during index hospitalization compared with unfractionated heparin in medically ill patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: